THE OBSERVATORY :: NEWS TRENDS ANALYSIS
Biomarkers that predict preeclampsia risk
photo credit Photo by © Steveheap |
Dreamstime.com Fast Facts
More than 3 million youth reported using a tobacco product in 2022
A study released from the U.S. Food and Drug Administration (FDA) and the U.S. Centers for Disease Control and Prevention (CDC) found that 3.08 million (11.3%) U.S. middle and high school students reported current (past 30-day) use of any tobacco product in 2022.
The study assessed eight commercial
tobacco products. Of the students that reported tobacco use:
2.51 million (16.5%) were high school students.
530,000 (4.5%) were middle school students.
2.55 million
reported using e-cigarettes, making it the most commonly used tobacco product among all students for the ninth consecutive year.
13.5%
of non-Hispanic American Indian or Alaska Native students reported
tobacco use, the highest percentage of all race and ethnicity groups.
1 million
youth reported using any combustible tobacco product.
27.2%
of students who reported tobacco use had grades of mostly Fs.
Source:
https://www.cdc.gov/media/re- leases/2022/
p1110-youth-tobaco.html
In a study of pregnant women in the United States, Cedars-Sinai investiga- tors found that a specific imbalance of two placental proteins could predict which women were at risk of developing a severe form of preeclampsia, a life- threatening blood pressure disorder. The study is published in the jour-
nal NEJM Evidence. The blinded, prospective study of
women initially hospitalized for preterm hypertension involved 1,014 patients from 18 hospitals across the nation. Investigators found that a specific
protein imbalance revealed in blood tests of the hospitalized pregnant women provided a way to quantify their risk of developing severe preeclampsia. It involves levels of soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PIGF) in the bloodstream.
NIH’s Climate and Health Initiative tackles global health effects associated with a changing climate
Leaders from the National Institutes of Health discuss the agency’s plan to address the risk to human health posed by a changing climate in a commentary published in The Lancet. As floods, hur- ricanes, tornados, wildfires, and heat waves become more extreme, the risk to human health grows, exacerbating existing health threats and creating new public health challenges around the world. The authors, a coalition of leaders at NIH, outline how the NIH Climate Change and Health Initiative is unique- ly poised to lead and engage with communities and agencies globally to address the health effects associated with climate change.
Effect of ivermectin vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19
A new study showed that among outpa- tients with mild to moderate COVID-19, treatment with ivermectin, compared with placebo, did not significantly im- prove time to recovery in this trial that enrolled more than 1,500 participants in the United States. A lack of treatment effect was also
seen for secondary clinical outcomes including hospitalization, death, or acute care visits. These findings do not support the use of ivermectin in patients with mild to moderate COVID-19. The study was published in JAMA.
6 DECEMBER 2022
MLO-ONLINE.COM
Cancer deaths continue downward trend; modest improvements in survival for pancreatic cancer
Overall cancer death rates contin- ued to decline among men, women, children, and adolescents and young adults in every major racial and ethnic group in the United States from 2015 to 2019, according to the latest Annual Report to the Nation on the Status of Cancer. From 2014 to 2018, overall cancer incidence, or new cases of cancer, remained stable for men and chil- dren but increased for women and adolescents and young adults. This year’s report, published October 27, 2022, in Cancer, also highlights longer- term trends in pancreatic cancer, as well as racial and ethnic disparities in incidence and death rates for many individual cancer sites.
All of the findings in this report are based on data from before the CO- VID-19 pandemic. The report shows that from 2015 to 2019, overall cancer death rates decreased by 2.1% per year in men and women combined. Among men, death rates decreased by 2.3% per year; among women, death rates decreased by 1.9% per year. The annual declines in death rate accelerated from 2001 to 2019 in both men and women. The declines in death rates were
steepest in lung cancer and melanoma (by 4% to 5% per year) among both men and women. Death rates increased for cancers of the pancreas, brain, and bones and joints among men, and for cancers of the pancreas and uterus among women. The report showed that cancer in- cidence rates were relatively stable in men and women combined from 2014 to 2018. Among men, incidence rates remained stable during this period, but among women incidence rates rose by 0.2% per year. Over the same time period, inci- dence rates increased for three of the 18 most common cancers among men: pancreas, kidney, and testis. In- cidence rates in men remained stable for seven of the most common cancers and decreased for the remaining eight cancers. For women, incidence rates increased for seven of the 18 most common cancers: liver, melanoma, kidney, myeloma, pancreas, breast, and oral cavity and pharynx. Inci- dence rates among women remained stable for four of the most common cancers and decreased for the other seven cancers.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
